Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of one chemical raw material and one drug, indicating a positive regulatory development for the company [1] Group 1: Product Approvals - The company received a "Chemical Raw Material Re-registration Approval Notice" for the chemical raw material named Povidone Iodine, which is used in various formulations such as Povidone Iodine solution and Povidone Iodine ointment [1] - The company also obtained a "Drug Re-registration Approval Notice" for the drug named Injection Gabexate Mesilate, which is used for the treatment of acute mild (edematous) pancreatitis and can also assist in the treatment of acute hemorrhagic necrotizing pancreatitis [1]

华森制药公告，公司近日收到重庆市药品监督管理局核准签发的1个化学原料药和1个药品的《再注册批 准通知书》。其中，化学原料药聚维酮碘受理号为CYHZ2427221渝，通知书编号为2025R088239，有效 期为24个月，至2030年09月21日。药品注射用甲磺酸加贝酯受理号为CYHZ2427236渝，通知书编号为 2025R089146，规格为0.1g，注册分类为化学药品，药品注册标准编号为YBH09332022，药品批准文号 有效期至2030年09月24日。此次再注册将确保药品的正常生产和销售，短期内不会对经营业绩产生重大 影响。 ...